Brian Lagreca, MD
Ophthalmology · Billings, MTNPI 1992840128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 67.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $216 and has fallen 92.0% since, to $17 in 2025.
Across 30 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$375
- Alimera Sciences, Inc.$35
- Iridex Corporation$25
- Novartis$24
- Tarsus Pharmaceuticals, Inc.$20
- Dompe US, Inc.$17
- plus $65 from 4 others
What the payments were for
- Food & beverage$559100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $375 |
| Alimera Sciences, Inc. | 2 | $35 |
| Iridex Corporation | 1 | $25 |
| Novartis | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Dompe US, Inc. | 1 | $17 |
| Glaukos Corporation | 1 | $17 |
| Amgen | 1 | $16 |
| Alcon | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$559 in reported general payments places this provider in the 55th percentile of 52 ophthalmology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 28 | $28,669 |
| LumiganBimatoprost | 63 | $25,435 |
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $16,690 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $7,914 |
| Ofloxacin | 535 | $6,232 |
| Prednisolone Acetate | 94 | $4,721 |
| VyzultaLatanoprostene Bunod | 13 | $4,221 |
| Latanoprost | 323 | $2,905 |
| Loteprednol Etabonate | 12 | $2,193 |
| Fluorometholone | 19 | $1,706 |
| Brimonidine Tartrate | 44 | $1,634 |
| ValacyclovirValacyclovir Hcl | 32 | $1,632 |
| Timolol Maleate | 105 | $1,461 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,151 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 59 | $969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $375 | $62,018127 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $2,19312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 52 ophthalmology providers in Montana.
Other ophthalmology in Billings
- Christopher ParisBillings$676
- James PriddyBillings$103
- Michael PowerBillings$100
- Daniel WeaverBillings$90
- David SwitzerBillings$42
- James ThreattBillings$37
- George HatchBillings$33
- Scott Morledge-HamptonBillings$21
- James CornetetBillings$17
- Curtis FrewinBillings$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.